Snapshot
Chemed Corp reported $639M of revenue in Q4 2025, up -0.1% year over year, with diluted EPS of $5.48 and an operating margin of 15.7%.
- Revenue
- $639M
- YoY growth
- +-0.1%
- Diluted EPS
- $5.48
- Operating margin
- 15.7%
$639M
Revenue
+-0.1%
YoY growth
$5.48
Diluted EPS
15.7%
Operating margin
01 Key takeaways
What management said
- •In addition, management may also discuss non-GAAP operating performance results during today's call, including earnings before interest, taxes, depreciation, and amortization, or EBITDA and adjusted EBITDA.
- •The second impact is that due to the overwhelming success of garnering elevated short-stay patient admissions, our revenue growth and EBITDA margin were lower than anticipated.
- •Ultimately, the percentage of total admissions that come from hospitals was higher than we originally budgeted in both the third and fourth quarters of 2025, resulting in this muted revenue growth and EBITDA margin.
- •In the guidance that Mike will discuss further, we have anticipated that the more balanced approach will start being reflected in financial results, mainly in the second half of the year.
- •As a result, refocusing the admission patterns will result in revenue growth and EBITDA margins building over the course of 2026.
- •Roto-Rooter revenue declined 3.7% in the fourth quarter of 2025 compared to the same period of 2024.
- •Branch commercial revenue increased 1.6% compared to the fourth quarter of 2024.
- •Branches with commercial business managers had percentage revenue increases, 10% more than those without them.
- •The decline in natural leads essentially offset the increase in paid leads.
- •A similar increase in write-offs was seen in the third quarter of 2025.
- •Our guidance reflects management's belief that 2026 is expected to be a transition year for both VITAS and Roto-Rooter.
- •We are very confident the Florida Medicare capital limitation in 2025 is fully behind us.
SourcesCompany financials · earnings call
Last updated